STAAR Surgical Company (STAA) News
Filter STAA News Items
STAA News Results
|Loading, please wait...|
STAA News Highlights
- STAA's 30 day story count now stands at 8.
- Over the past 16 days, the trend for STAA's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- ICL, EVO and EYE are the most mentioned tickers in articles about STAA.
Latest STAA News From Around the Web
Below are the latest news stories about STAAR SURGICAL CO that investors may wish to consider to help them evaluate STAA as an investment opportunity.
Should Weakness in STAAR Surgical Company's (NASDAQ:STAA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
With its stock down 18% over the past month, it is easy to disregard STAAR Surgical (NASDAQ:STAA). However, the...
LAKE FOREST, Calif., November 15, 2023--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced that management will participate in the Stephens Annual Investment Conference on Thursday, November 16, 2023.
STAAR Surgical Company (NASDAQ:STAA) Q3 2023 Earnings Call Transcript November 1, 2023 STAAR Surgical Company beats earnings expectations. Reported EPS is $0.3, expectations were $0.2. Operator: Good day ladies and gentlemen. Thank you for standing by. Welcome to the STAAR Surgical Third Quarter Financial Results Conference Call. During today’s presentation, all parties will be in […]
Q3 2023 STAAR Surgical Co Earnings Call
While the top- and bottom-line numbers for Staar Surgical (STAA) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ICL Sales Up 13% Y/Y, Marking 23rd Consecutive Quarter of Double-Digit ICL Sales Growth
LAKE FOREST, Calif., November 01, 2023--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today reported financial results for the third quarter ended September 29, 2023.
Investment firm Anatole Investment Management called on STAAR Surgical Company to consider spinning off its Asia or China business, arguing the standalone China business could be worth as much as $5 billion, according to its letter to the company. Hong Kong-based Anatole, which owns roughly 4.2% of the Monrovia, California headquartered company's shares, said STAAR is undervalued and not reaching its "huge growth potential." STAAR designs, makes and sells lenses that can be implanted during eye surgeries.
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...
LAKE FOREST, Calif., October 18, 2023--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the third quarter ended September 29, 2023 on Wednesday, November 1, 2023 after the market close.